OncoMatch

OncoMatch/Clinical Trials/NCT05983276

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Is NCT05983276 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Decitabine and Carboplatin for ovarian cancer.

Phase 2RecruitingLoyola UniversityNCT05983276Data as of May 2026

Treatment: Decitabine · Carboplatin · Paclitaxel · SelinexorThe goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and paclitaxel) on patients with relapsed ovarian, fallopian or primary peritoneal carcinoma. Recently the investigators have found that the combination of decitabine and selinexor, two Food and Drug Administration (FDA) approved chemotherapy agents, may prevent or reverse the development of drug resistance and further the remissions and duration of remissions with standard ovarian cancer chemotherapy with carboplatin and paclitaxel. As decitabine and selinexor are not FDA approved for the participant's cancer, these agents are investigational.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: platinum-based chemotherapy

failed or relapsed after a platinum and taxane containing combination

Must have received: taxane

failed or relapsed after a platinum and taxane containing combination

Cannot have received: Selinexor or another XPO1 inhibitor

must not have received Selinexor or another XPO1 inhibitor previously

Cannot have received: chemotherapy

must not have had prior chemotherapy or radiation therapy

Cannot have received: radiation therapy

must not have had prior chemotherapy or radiation therapy

Lab requirements

Kidney function

adequate renal function

Liver function

adequate hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Loyola University Medical Center · Maywood, Illinois

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify